DGAP-News: CureVac und Novartis unterzeichnen initiale Vereinbarung zur Produktion des COVID-19-Impfstoffkandidaten CVnCoV finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Grapes may act as an edible sunscreen: Study New human research has found that consuming grapes can protect against ultraviolet (UV) skin damage and polyphenols are the likely culprit.
The two-part study, funded by the California Table Grapes Commission, was published in the
Journal of the American Academy of Dermatology and revealed that the subjects displayed increased resistance to sunburn and a reduction in markers of UV damage at the cellular level.
Study details
The research was conducted at the University of Alabama, Birmingham and led by principal investigator Craig Elmets, MD. Elmets et al investigated the impact of consuming whole grape powder - equivalent to 2.25 cups of grapes per day - for 14 days against photodamage from UV light.
DGAP-News: CureVac kündigt den Abschluss des öffentlichen Zeichnungsangebots mit einem Erlös von 450 Millionen US-Dollar an boersennews.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from boersennews.de Daily Mail and Mail on Sunday newspapers.
DGAP-News: CureVac / Key word: Financing/Corporate Action CureVac Announces Pricing of USD450 million Follow-on Public Offering of Common Shares 2021-01-28 / 07:00 The issuer is solely responsible.
BioArctic receives European patent for new antibodies targeting Alzheimer s disease
STOCKHOLM, Jan. 27, 2021 /PRNewswire/
BioArctic AB (publ) (Nasdaq Stockholm: BIOA B) announced today that the European Patent Office (EPO) has issued a decision to grant European patent EP 2 448 968 B1 for novel antibodies that could be developed into a treatment for Alzheimer s disease. The antibodies target a shorter (truncated) form of amyloid beta (pE3-Aß) and are linked to the company s project AD1503. The patent enters into force on 27 January 2021 and expires in 2030.
BioArctic s newly granted patent focuses on novel antibodies which target pE3-Ab, a specific truncated form of amyloid beta. Monomers of pE3-Ab are highly prone to aggregate, leading to the formation of harmful soluble Ab aggregates which cause debilitating cognitive and other symptoms in Alzheimer s disease.